Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency

European Journal of Medical Research

Volumn 15, Issue 6, 2010, Pages 238-245

  Hoffmann, Florian ^a   Grimbacher, B ^b   Thiel, J ^b   Peter, H H ^b   Belohradsky, B H ^a   Ebell, Wolfram ^c   Gruhn, Bernd ^d   Jacobs, Georg ^e   Kindler, Birgit ^f   Kindler, Manfred ^f   Mannhardt Laakmann, Wilma ^g   Peters, Ove ^h   Schuize, Ilka ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Klinik fur Kinder und Jugendmedizin   (Germany)

^e Schwerpunktpraxis fur Hamatologie O   (Germany)

^f Onkologische Schwerpunktpraxis   (Germany)

^g Zentrum fur Kinder und Jugendmedizin   (Germany)

^h KRANKENHAUS BARMHERZIGE BRÜDER   (Germany)

Author keywords

Adults; Antibody deficiency; Children; Quality of life; Subcutaneous immunoglobulin therapy

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; HUMAN IMMUNOGLOBULIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EMOTION; FAMILY ASSESSMENT; FEMALE; HEALTH STATUS; HOME CARE; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; LIFE EVENT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PAIN; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; QUALITY OF LIFE; SCHOOL CHILD; SHORT FORM 36; STRUCTURED QUESTIONNAIRE; SUBSTITUTION THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING; CHILD HEALTH QUESTIONNAIRE PARENTAL FORM 50; CHRONIC LYMPHATIC LEUKEMIA; COMMON VARIABLE IMMUNODEFICIENCY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL MOTILITY DISORDER; HEALTH ASSESSMENT QUESTIONNAIRE; HYPERTHERMIA; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PATIENT PREFERENCE; PROSPECTIVE STUDY; SELF REPORT; SKIN REDNESS; SWELLING; TISSUE REACTION; X LINKED AGAMMAGLOBULINEMIA;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; INFANT; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77954393427     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Yong PF, Tarzi M, Chua I, et al. Common variable immunodeficiency: an update on etiology and management. Immunol Allergy Clin North Am. 2008; 28(2): 367-86, ix-x.
2. Pan-Hammarström Q, Hammarström L. Antibody deficiency diseases. Eur J Immunol. 2008; 38(2): 327-33.
3. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999; 92(1): 34-48. (Pubitemid 29315984)
4. Grimbacher B, Warnatz K, Peter HH. Der variable Immundefekt (Common variable immunodeficiency). 2003; http://www.cvid.info/de/ BaxterUniFreiburg%2072dpi.pdf (Accessed: 26 Nov 2009).
5. Buckley RH. Primary immunodeficiency diseases: dissectors of the immune system. Immunol Rev. 2002; 185: 206-19.
6. Kirmse J. Subcutaneous administration of immunoglobulin. J Infus Nurs. 2006; 29(3 Suppl): S15-20.
7. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006; 46(5): 741-53.
8. Radinsky S, Bonagura VR. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J Allergy Clin Immunol. 2003; 112(3): 630-3. (Pubitemid 37108574)
9. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies - a prospective, multi-national study. J Clinical Immunol. 2006; 26: 177-85.
10. Weiler CR. Immunoglobulin therapy: history, indications, and routes of administration. Int J Dermatol. 2004; 43: 163-6.
11. Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995; 345: 365-9.
12. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004; 112: 1-7. (Pubitemid 38781052)
13. Gustafson R, Hammarström L. Subcutaneous immunoglobulin replacement therapy. Ellipse. 2002; 18: 45-8.
14. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007; 21(2): 105-16. (Pubitemid 46624555)
15. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998; 79: 48-51. (Pubitemid 28331253)
16. Gardulf A, Björvell H, Andersen V, et al. Lifelong treatment with gammaglobulin to patients with primary antibody deficiencies: The patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs. 1995; 21: 917-27.
17. Sigstad HM, Stray-Pedersen A, Frøland SS. Coping, quality of life, and hope in adults with primary antibody deficiencies. Health Qual Life Outcomes. 2005; 3: 31.
18. Fasth A, Nyström J. Quality of life and health-care resource utilization among children with primary immunodeficiency receiving home treatment with subcutaneous human immunoglobulin. J Clin Immunol. 2008; 28(4): 370-8.
19. Gardulf A, Nicolay U, Asensio O, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004; 114: 936-42.
20. Gardulf A, Nicolay U. Replacement IgG therapy and selftherapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006; 6: 434-42. (Pubitemid 44714156)
21. Gardulf A, Borte M, Ochs HD, et al. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. 2008; 126: 81-8.
22. Conference Report, Network of Rare Blood Disorder Organizations, Conference on Comprehensive Care for Rare Blood Disorders, February 3-5, 2006, Toronto, Ontario.
23. Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics. 1996; 98: 1127-31. (Pubitemid 26399277)
24. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473-83.
25. Ware JE Jr, Snow KK, Kosinski M. SF-36 health survey: manual and interpretation guide. Lincoln (RI): Quality-Metric Inc; 2000.
26. Landgraf J, Abetz L, Ware JE Jr. The Child Health Questionnaire (CHQ), a user's manual. 2nd ed. Boston: The Health Institute; 1999.
27. Gardulf A, Björvell H, Gustafson R, et al. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol. 1993; 92(2): 200-4. (Pubitemid 23151026)
28. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunodeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006; 26(1): 65-72.
29. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000; 20(2): 94-100. (Pubitemid 30314313)
30. Singh-Grewal D, Kemp A, Wong M. A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions. Arch Dis Child. 2006; 91(8): 651-4. (Pubitemid 44197104)
31. Kittner JM, Grimbacher B, Wulff W, et al. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006; 26(4): 400-5. (Pubitemid 44051388)
32. Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007; 96(10): 1474-8.